Literature DB >> 3009061

Studies of EBV-lymphoid cell interactions in two patients with the X-linked lymphoproliferative syndrome: normal EBV-specific HLA-restricted cytotoxicity.

F Rousset, G Souillet, M G Roncarolo, J P Lamelin.   

Abstract

Two X-linked lymphoproliferative syndrome (XLP) patients with the hypogammaglobulinemia phenotype were investigated at a time remote from their primary infection with the Epstein-Barr virus (EBV). The lymphoblastoid cell lines derived from these patients expressed the phenotypic markers characteristic of normal mature B lymphocytes and produced normal levels of immunoglobulins (Ig). These observations imply that at least some of their B cells are phenotypically normal. The natural killer (NK) activity of the two patients was low. In one patient, activated lymphocyte killer (ALK) activity was inefficient. These two XLP patients expressed a normal EBV-specific, HLA-restricted cytotoxic activity. It thus appears, from the present findings and those in cases published previously (6/11 patients expressing normal EBV-specific cytotoxic activity), that the notion of poor specific T cell memory for EBV may not be as pivotal ass suggested or, alternatively, that this defect may not be common in hypogammaglobulinemic survivors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009061      PMCID: PMC1577389     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  Prevalence of oropharyngeal excreters of leukocyte-transforming agents among a human population.

Authors:  R S Chang; J P Lewis; C F Abildgaard
Journal:  N Engl J Med       Date:  1973-12-20       Impact factor: 91.245

3.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

4.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

5.  Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs.

Authors:  B Strauch; L L Andrews; N Siegel; G Miller
Journal:  Lancet       Date:  1974-02-16       Impact factor: 79.321

6.  Chromosome studies of cell lines and tumors derived from a single specimen of human leukemic blood by cell culture and heterotransplantation.

Authors:  A Krishan; R Raychaudhuri
Journal:  Cancer Res       Date:  1970-07       Impact factor: 12.701

7.  Pathogenesis and phenotypes of an X-linked recessive lymphoproliferative syndrome.

Authors:  D T Purtilo
Journal:  Lancet       Date:  1976-10-23       Impact factor: 79.321

8.  T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A.

Authors:  A B Rickinson; M Rowe; I J Hart; Q Y Yao; L E Henderson; H Rabin; M A Epstein
Journal:  Cell Immunol       Date:  1984-09       Impact factor: 4.868

9.  X-linked recessive progressive combined variable immunodeficiency (Duncan's disease).

Authors:  D T Purtilo; C K Cassel; J P Yang; R Harper
Journal:  Lancet       Date:  1975-04-26       Impact factor: 79.321

10.  Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.

Authors:  G Klein; T Lindahl; M Jondal; W Leibold; J Menézes; K Nilsson; C Sundström
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

View more
  4 in total

1.  Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.

Authors:  M Yanagisawa; M Kato; K Ikeno; T Kobayashi; Y Miyagawa; A Komiyama; T Akabane
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

Review 2.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

Review 3.  Immune regulation in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows; D J Moss
Journal:  Microbiol Rev       Date:  1995-09

Review 4.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.